GILD Gilead Sciences

XNGS Up Alert

Health Care

· How we analyze

About the company

Gilead Sciences is a US biotechnology company. Its focus is drugs for HIV, hepatitis B and C and cancer therapies, including cell therapies. Well-known products include the HIV drug Biktarvy and the Covid drug Veklury. As of Oct 11, 2026

Fact sheet (from the annual report) Biotechnology and vaccines · Foster City, USA

The biopharmaceutical company, based in Foster City, offers medicines for HIV, viral hepatitis, COVID and cancer. For HIV it markets Biktarvy and Descovy, among others. In liver disease it markets Epclusa for chronic hepatitis C, also as an authorized generic through a subsidiary. In oncology it offers a cell therapy for certain forms of lymphoma and leukemia and an antibody-drug conjugate for certain forms of breast cancer. In the US market, sales and distribution of most products run exclusively through wholesalers, mainly Cardinal Health, Cencora and McKesson. Outside the US market it sells through its own teams, external distributors or partners, and manufacturing is in part done by contract manufacturers.

Automatically summarized from SEC annual report (10-K, filed Feb 24, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

What the methods say about Gilead Sciences

Calculated automatically by fixed rules – not investment advice, check for yourself. How we analyze

Price performance at a glance

Last 30 trading days
  • Today +0.3%
  • 7 days +1.6%
  • 30 days +5.4%
  • 1 year +32.1%
Day range (last trading day)
−2.1%Price at 94% of the range+0.1%
52-week range
−28.3%Price at 97% of the range+0.9%
Distance from the all-time high
−0.9%

Our own calculation from the exchange’s daily candles, as of Oct 27, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Load chart from TradingView

This transfers data (including your IP address) to TradingView, also to the USA. More in the Privacy policy.

Symbol on TradingView: NASDAQ:GILD

Fundamental analysis

Gilead Sciences · Sector Health Care · amounts in USD

Information only – does not affect the other analysis methods, not investment advice. Source: SEC filings, As of Feb 24, 2026.

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality Profitability, consistency, balance sheet 8 of 8 criteria met Growth Revenue and earnings per share 3 of 7 criteria met Dividend Level, consistency, coverage · 1 without data 6 of 6 criteria met Financial strength Piotroski, debt, liquidity 6 of 6 criteria met

Quality 8 of 8 met

  • met: Gross margin above 40% 78.8%
  • met: Operating margin above 15% 34.0%
  • met: Net margin above 10% 28.9%
  • met: Return on equity above 15% 37.5%
  • met: Free cash flow margin above 10% 32.1%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • met: Equity ratio above 30% 38.5%
Gross margin

78.8% Fiscal year 2025

Rank 91 of 100: higher than 91% of 153 peers (All). strong.

Rank 83 of 100: higher than 83% of 20 peers (Sector). strong.

Median Health Care: 66.6%

Share of revenue left after the direct cost of the products sold.

Operating margin

34.0% Fiscal year 2025

Rank 84 of 100: higher than 84% of 192 peers (All). strong.

Rank 88 of 100: higher than 88% of 20 peers (Sector). strong.

Median Health Care: 18.0%

Operating income divided by revenue: what the core business earns before interest and taxes.

Net margin

28.9% Fiscal year 2025

Rank 82 of 100: higher than 82% of 237 peers (All). strong.

Rank 83 of 100: higher than 83% of 26 peers (Sector). strong.

Median Health Care: 13.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

37.5% Fiscal year 2025

Rank 81 of 100: higher than 81% of 218 peers (All). strong.

Rank 83 of 100: higher than 83% of 21 peers (Sector). strong.

Median Health Care: 14.3%

Net income divided by equity at fiscal year end.

Return on assets

14.4% Fiscal year 2025 (total assets at year end)

Rank 83 of 100: higher than 83% of 238 peers (All). strong.

Rank 87 of 100: higher than 87% of 26 peers (Sector). strong.

Median Health Care: 6.4%

Net income divided by total assets at fiscal year end.

Equity ratio

38.5% Fiscal year 2025

Rank 55 of 100: higher than 55% of 239 peers (All). medium.

Rank 52 of 100: higher than 52% of 26 peers (Sector). medium.

Median Health Care: 38.5%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

32.1% Fiscal year 2025

Rank 86 of 100: higher than 86% of 213 peers (All). strong.

Rank 98 of 100: higher than 98% of 25 peers (Sector). strong.

Median Health Care: 14.9%

Free cash flow divided by revenue.

Free cash flow

9.5B USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 3 of 7 met

  • not met: Over 3 years, revenue grew by more than 5% per year +2.6%
  • not met: Over 5 years, revenue grew by more than 5% per year +3.6%
  • not met: Over 10 years, revenue grew by more than 5% per year −1.0%
  • met: Over 3 years, EPS grew by more than 5% per year +23.0%
  • met: Over 5 years, EPS grew by more than 5% per year +132.4%
  • not met: Revenue rose in at least 4 of the last 5 fiscal years 3 of 5
  • met: Revenue rose in the last fiscal year +2.4%
Revenue growth 3 years

+2.6% per year

Rank 25 of 100: higher than 25% of 230 peers (All). weak.

Rank 38 of 100: higher than 38% of 25 peers (Sector). medium.

Median Health Care: +5.6%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+3.6% per year

Rank 14 of 100: higher than 14% of 217 peers (All). weak.

Rank 14 of 100: higher than 14% of 25 peers (Sector). weak.

Median Health Care: +8.5%

Average growth per year over 5 fiscal years.

Revenue growth 10 years

−1.0% per year

Rank 7 of 100: higher than 7% of 157 peers (All). weak.

Rank 3 of 100: higher than 3% of 19 peers (Sector). weak.

Median Health Care: +10.1%

Average growth per year over 10 fiscal years.

EPS growth 3 years

+23.0% per year

Rank 74 of 100: higher than 74% of 157 peers (All). strong.

Rank 89 of 100: higher than 89% of 22 peers (Sector). strong.

Median Health Care: +5.5%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 5 years

+132.4% per year

Rank 98 of 100: higher than 98% of 146 peers (All). strong.

Rank 98 of 100: higher than 98% of 20 peers (Sector). strong.

Median Health Care: +7.0%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 10 years

−5.5% per year

Rank 5 of 100: higher than 5% of 140 peers (All). weak.

Rank 8 of 100: higher than 8% of 20 peers (Sector). weak.

Median Health Care: +8.3%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 6 of 6 met · 1 without data

  • met: Pays a dividend 3.16 USD
  • met: Payout ratio at most 60% of earnings 47%
  • met: Dividend paid in each of the last 5 fiscal years 5 of 5
  • met: Dividend per share never lowered in the last 5 fiscal years Dividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut. never
  • no data: Dividend per share higher than 5 years ago no comparable dividend 5 years ago
  • met: Free cash flow per share covers the dividend 2.4x
  • met: Dividends paid over the last 5 years covered by free cash flow 41% of free cash flow
Payout ratio

47% Fiscal year 2025

Dividend per share divided by earnings per share.

Free cash flow coverage

2.4x Fiscal year 2025

Free cash flow per share divided by dividend per share. From 1x the dividend is covered.

Financial strength 6 of 6 met

  • met: Piotroski F-Score at least 7 of 9 8 of 9
  • met: Long-term debt no higher than equity 0.97
  • met: Current assets cover current liabilities 1.55
  • met: Positive equity 22.7B USD
  • met: In 5 years, share count up by at most 5% −0.6%
  • met: Free cash flow positive in the last fiscal year 9.5B USD
Piotroski F-Score

8 of 9 Fiscal year 2025

Rank 90 of 100: higher than 90% of 134 peers (All). strong.

Rank 92 of 100: higher than 92% of 19 peers (Sector). strong.

Median Health Care: 7.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

0.97 at fiscal year end

Rank 33 of 100: lower than 33% of 199 peers (All). medium.

Rank 19 of 100: lower than 19% of 18 peers (Sector). weak.

Median Health Care: 0.72

Long-term financial debt divided by equity.

Liquidity (current ratio)

1.55 at fiscal year end

Rank 56 of 100: higher than 56% of 215 peers (All). medium.

Rank 48 of 100: higher than 48% of 26 peers (Sector). medium.

Median Health Care: 1.56

Current assets divided by current liabilities.

Change in share count

−0.6% in 5 years

Rank 46 of 100: lower than 46% of 199 peers (All). medium.

Rank 31 of 100: lower than 31% of 24 peers (Sector). weak.

Median Health Care: −2.7%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • met: Long-term debt relative to total assets fell
  • not met: Liquidity (current assets / current liabilities) rose
  • met: No additional shares (diluted share count did not rise)
  • met: Gross margin higher than the prior year
  • met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light yellow: Revenue grew over 5 years (+3.6% per year), more slowly than the sector median.
  • Light green: Net income (total) grew over 5 years (+133.3% per year), at least as fast as the sector median; per share +132.4% per year.
  • Light green: Net margin 28.9%, above the sector median (12.9%).
  • Light red: Debt much higher than usual in the sector.
  • Light green: Profit in each of the last 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 30.4B USD · Net income 13.5B USD · Net margin 44.4%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 26.1B USD · Net income 4.6B USD · Net margin 17.7%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 22.1B USD · Net income 5.5B USD · Net margin 24.7%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 22.4B USD · Net income 5.4B USD · Net margin 24.0%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 24.7B USD · Net income 123.0M USD · Net margin 0.5%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 27.3B USD · Net income 6.2B USD · Net margin 22.8%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 27.3B USD · Net income 4.6B USD · Net margin 16.8%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 27.1B USD · Net income 5.7B USD · Net margin 20.9%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 28.8B USD · Net income 480.0M USD · Net margin 1.7%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 29.4B USD · Net income 8.5B USD · Net margin 28.9%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 29.4B USD · Net income 8.5B USD · Net margin 28.9%

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 78.8 USD gross profit, 34.0 USD operating income and 28.9 USD net income remained.

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue29.4B USD100.0%
Gross profit23.2B USD78.8%
Cost of revenue6.2B USD21.2%
Operating income10.0B USD34.0%
Research & development5.8B USD19.7%
Other operating expenses7.4B USD25.1%
Net income8.5B USD28.9%
Interest expense1.0B USD3.5%
Taxes & other (net)488.0M USD1.7%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin rose in 5 years from 16.5% to 34.0%.

Gross marginOperating marginNet margin
  1. Fiscal year 2016: Gross margin 86.0% · Operating margin 58.0% · Net margin 44.4%
  2. Fiscal year 2017: Gross margin 83.3% · Operating margin 54.1% · Net margin 17.7%
  3. Fiscal year 2018: Gross margin 78.1% · Operating margin 37.1% · Net margin 24.7%
  4. Fiscal year 2019: Gross margin not available · Operating margin 19.1% · Net margin 24.0%
  5. Fiscal year 2020: Gross margin not available · Operating margin 16.5% · Net margin 0.5%
  6. Fiscal year 2021: Gross margin 75.8% · Operating margin 36.3% · Net margin 22.8%
  7. Fiscal year 2022: Gross margin 79.3% · Operating margin 26.9% · Net margin 16.8%
  8. Fiscal year 2023: Gross margin 76.0% · Operating margin 28.0% · Net margin 20.9%
  9. Fiscal year 2024: Gross margin not available · Operating margin 5.8% · Net margin 1.7%
  10. Fiscal year 2025: Gross margin 78.8% · Operating margin 34.0% · Net margin 28.9%

Returns

Return on equity rose in 5 years from 0.7% to 37.5%.

Return on equityReturn on assets
  1. Fiscal year 2016: Return on equity 71.5% · Return on assets 23.7%
  2. Fiscal year 2017: Return on equity 22.6% · Return on assets 6.6%
  3. Fiscal year 2018: Return on equity 25.5% · Return on assets 8.6%
  4. Fiscal year 2019: Return on equity 23.9% · Return on assets 8.7%
  5. Fiscal year 2020: Return on equity 0.7% · Return on assets 0.2%
  6. Fiscal year 2021: Return on equity 29.5% · Return on assets 9.2%
  7. Fiscal year 2022: Return on equity 21.6% · Return on assets 7.3%
  8. Fiscal year 2023: Return on equity 24.8% · Return on assets 9.1%
  9. Fiscal year 2024: Return on equity 2.5% · Return on assets 0.8%
  10. Fiscal year 2025: Return on equity 37.5% · Return on assets 14.4%

Equity and long-term debt

The equity ratio rose in 5 years from 26.6% to 38.5%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2016: Equity 18.9B USD · Long-term debt 26.3B USD
  2. Fiscal year 2017: Equity 20.4B USD · Long-term debt 30.8B USD
  3. Fiscal year 2018: Equity 21.4B USD · Long-term debt 24.6B USD
  4. Fiscal year 2019: Equity 22.5B USD · Long-term debt 22.1B USD
  5. Fiscal year 2020: Equity 18.2B USD · Long-term debt 28.6B USD
  6. Fiscal year 2021: Equity 21.1B USD · Long-term debt 25.2B USD
  7. Fiscal year 2022: Equity 21.2B USD · Long-term debt 23.0B USD
  8. Fiscal year 2023: Equity 22.8B USD · Long-term debt 23.2B USD
  9. Fiscal year 2024: Equity 19.3B USD · Long-term debt 24.9B USD
  10. Fiscal year 2025: Equity 22.7B USD · Long-term debt 22.1B USD

Liquidity (current ratio)

The current ratio rose in 5 years from 1.40 to 1.55.

Current ratio
  1. Fiscal year 2016: Current ratio 2.22
  2. Fiscal year 2017: Current ratio 2.74
  3. Fiscal year 2018: Current ratio 3.38
  4. Fiscal year 2019: Current ratio 3.10
  5. Fiscal year 2020: Current ratio 1.40
  6. Fiscal year 2021: Current ratio 1.27
  7. Fiscal year 2022: Current ratio 1.29
  8. Fiscal year 2023: Current ratio 1.43
  9. Fiscal year 2024: Current ratio 1.60
  10. Fiscal year 2025: Current ratio 1.55

Cash flow

Free cash flow rose in 5 years from 7.5B USD to 9.5B USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 16.7B USD · Capital expenditure 748.0M USD · Free cash flow 15.9B USD
  2. Fiscal year 2017: Operating cash flow 11.9B USD · Capital expenditure 590.0M USD · Free cash flow 11.3B USD
  3. Fiscal year 2018: Operating cash flow 8.4B USD · Capital expenditure 924.0M USD · Free cash flow 7.5B USD
  4. Fiscal year 2019: Operating cash flow 9.1B USD · Capital expenditure 825.0M USD · Free cash flow 8.3B USD
  5. Fiscal year 2020: Operating cash flow 8.2B USD · Capital expenditure 650.0M USD · Free cash flow 7.5B USD
  6. Fiscal year 2021: Operating cash flow 11.4B USD · Capital expenditure 579.0M USD · Free cash flow 10.8B USD
  7. Fiscal year 2022: Operating cash flow 9.1B USD · Capital expenditure 728.0M USD · Free cash flow 8.3B USD
  8. Fiscal year 2023: Operating cash flow 8.0B USD · Capital expenditure 585.0M USD · Free cash flow 7.4B USD
  9. Fiscal year 2024: Operating cash flow 10.8B USD · Capital expenditure 523.0M USD · Free cash flow 10.3B USD
  10. Fiscal year 2025: Operating cash flow 10.0B USD · Capital expenditure 563.0M USD · Free cash flow 9.5B USD

Share count

The share count stayed roughly the same in 5 years.

Diluted share count
  1. Fiscal year 2016: Diluted share count 1.4B
  2. Fiscal year 2017: Diluted share count 1.3B
  3. Fiscal year 2018: Diluted share count 1.3B
  4. Fiscal year 2019: Diluted share count 1.3B
  5. Fiscal year 2020: Diluted share count 1.3B
  6. Fiscal year 2021: Diluted share count 1.3B
  7. Fiscal year 2022: Diluted share count 1.3B
  8. Fiscal year 2023: Diluted share count 1.3B
  9. Fiscal year 2024: Diluted share count 1.3B
  10. Fiscal year 2025: Diluted share count 1.3B

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
3.16 USD · Fiscal year 2025
Dividend growth per year
3 y +2.7%5 y –10 y +9.4%
Years without a cut
at least 4 as far as the data goes
Payout ratio
of earnings 47% of free cash flow 42%
To shareholders (5 years)
25.1B USD 24% through repurchases
Share count over 5 years
−0.6% roughly unchanged

Dividend per share

The dividend per share rose in 4 years from 2.84 USD to 3.16 USD.

Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.
  1. Fiscal year 2016: Dividend per share 1.84 USD
  2. Fiscal year 2017: Dividend per share 2.08 USD
  3. Fiscal year 2018: Dividend per share 2.28 USD
  4. Fiscal year 2019: Dividend per share 2.52 USD
  5. Fiscal year 2020: Dividend per share not available
  6. Fiscal year 2021: Dividend per share 2.84 USD
  7. Fiscal year 2022: Dividend per share 2.92 USD
  8. Fiscal year 2023: Dividend per share 3.00 USD
  9. Fiscal year 2024: Dividend per share 3.08 USD
  10. Fiscal year 2025: Dividend per share 3.16 USD

Payout ratios

The payout ratio fell in 4 years from 57.6% to 46.6%.

Payout ratio (earnings)Payout ratio (free cash flow) Ratios above 500% hidden (earnings or free cash flow close to zero).
  1. Fiscal year 2016: Payout ratio (earnings) 18.5% · Payout ratio (free cash flow) 15.4%
  2. Fiscal year 2017: Payout ratio (earnings) 59.3% · Payout ratio (free cash flow) 24.2%
  3. Fiscal year 2018: Payout ratio (earnings) 54.7% · Payout ratio (free cash flow) 39.7%
  4. Fiscal year 2019: Payout ratio (earnings) 59.7% · Payout ratio (free cash flow) 38.7%
  5. Fiscal year 2020: Payout ratio (earnings) not available · Payout ratio (free cash flow) 45.9%
  6. Fiscal year 2021: Payout ratio (earnings) 57.6% · Payout ratio (free cash flow) 33.4%
  7. Fiscal year 2022: Payout ratio (earnings) 80.2% · Payout ratio (free cash flow) 44.5%
  8. Fiscal year 2023: Payout ratio (earnings) 66.7% · Payout ratio (free cash flow) 51.3%
  9. Fiscal year 2024: Payout ratio (earnings) not available · Payout ratio (free cash flow) 38.0%
  10. Fiscal year 2025: Payout ratio (earnings) 46.6% · Payout ratio (free cash flow) 42.3%

What goes back to shareholders

Over 5 years, 25.1B USD went back to shareholders, 24% of it through share repurchases. That is 54% of the free cash flow of those years. This was offset by new shares issued for 1.5B USD (including employee plans).

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2016: Dividends paid 2.5B USD · Share repurchases 11.0B USD · New shares issued (including employee plans) 208.0M USD · Free cash flow 15.9B USD
  2. Fiscal year 2017: Dividends paid 2.7B USD · Share repurchases 954.0M USD · New shares issued (including employee plans) 234.0M USD · Free cash flow 11.3B USD
  3. Fiscal year 2018: Dividends paid 3.0B USD · Share repurchases 2.9B USD · New shares issued (including employee plans) 289.0M USD · Free cash flow 7.5B USD
  4. Fiscal year 2019: Dividends paid 3.2B USD · Share repurchases 1.7B USD · New shares issued (including employee plans) 209.0M USD · Free cash flow 8.3B USD
  5. Fiscal year 2020: Dividends paid 3.4B USD · Share repurchases 1.6B USD · New shares issued (including employee plans) 256.0M USD · Free cash flow 7.5B USD
  6. Fiscal year 2021: Dividends paid 3.6B USD · Share repurchases 546.0M USD · New shares issued (including employee plans) 169.0M USD · Free cash flow 10.8B USD
  7. Fiscal year 2022: Dividends paid 3.7B USD · Share repurchases 1.4B USD · New shares issued (including employee plans) 309.0M USD · Free cash flow 8.3B USD
  8. Fiscal year 2023: Dividends paid 3.8B USD · Share repurchases 1.0B USD · New shares issued (including employee plans) 232.0M USD · Free cash flow 7.4B USD
  9. Fiscal year 2024: Dividends paid 3.9B USD · Share repurchases 1.2B USD · New shares issued (including employee plans) 422.0M USD · Free cash flow 10.3B USD
  10. Fiscal year 2025: Dividends paid 4.0B USD · Share repurchases 1.9B USD · New shares issued (including employee plans) 408.0M USD · Free cash flow 9.5B USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Gilead Sciences next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison GILD, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
BMY Bristol Myers Squibb 48.2B USD +2.5%71.1%–14.6%38.2%20.5%26.7%8/9
TMO Thermo Fisher Scientific 44.6B USD +6.7%–17.4%15.0%12.6%48.4%14.1%–
ABT Abbott Laboratories 44.3B USD +5.1%56.4%18.2%14.7%12.5%60.1%16.7%6/9
AMGN Amgen 36.8B USD +7.6%67.2%24.7%21.0%89.1%9.6%22.0%7/9
MDT Medtronic 36.4B USD +3.8%65.0%17.8%13.2%9.7%53.2%14.9%7/9
GILD Gilead Sciences this stock 29.4B USD +3.6%78.8%34.0%28.9%37.5%38.5%32.1%8/9
SYK Stryker Corporation 25.1B USD +11.8%64.0%19.5%12.9%14.5%46.9%17.1%6/9
DHR Danaher Corporation 24.6B USD +2.0%59.1%19.1%14.7%6.9%62.9%21.4%7/9
REGN Regeneron Pharmaceuticals 14.3B USD +11.0%–24.9%31.4%14.4%77.1%28.4%–
Median of the sector 26 symbols 44.4B USD +8.5%66.6%18.0%13.9%14.3%38.5%14.9%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Figures of the last fiscal year from SEC annual reports (peers as of Oct 28, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light yellow: below sector

+3.6% per year, last 5 years

Sector Health Care: median +7.8% (60 symbols)

What does this mean? Revenue: over 5 years it grew by 3.6% per year on average, but more slowly than the median company in the sector (+7.8%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light green: above sector

+133.3% per year, last 5 years

Sector Health Care: median +7.5% (46 symbols)

per share: +132.4% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it grew by 133.3% per year on average – at least as fast as the median company in the sector (+7.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light green: above sector

28.9% last fiscal year

Sector Health Care: median 12.9% (63 symbols)

What does this mean? Of every 100 USD in revenue, 28.90 USD remained as profit – at least as much as the median company in the sector (12.9%). Five years ago the margin was 0.5%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light red: much higher

2.22 latest balance sheet

Sector Health Care: median 0.66 (49 symbols)

What does this mean? For every 1 USD of equity there is 2.22 USD of financial debt – more than twice as much as the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light green: covered

47% Dividend / earnings per share

Sector Health Care: median 28% (31 symbols)

What does this mean? Of every 1 USD of earnings per share, 0.47 USD went to shareholders as a dividend. The rest stays in the company. Median company in the sector: 28%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
29.4B USD
Revenue vs. prior year
+2.4%
Net income (FY)
8.5B USD
Net income vs. prior year
+1,672.9%
EPS (FY)
6.78 USD
13F funds with a position
2 of 9
Funds vs. prior quarter
±0
Shares held vs. prior quarter
+2,151.6%
Fiscal year to Dec 31, 2025 · 10-K filed Feb 24, 2026 · Balance sheet Jun 30, 2026 (filed Aug 6, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). 13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 29.4B8.5B 28.9% 6.78 3.16 47%
2024Dec 31, 2024 28.8B480.0M 1.7% 0.38 3.08 811%
2023Dec 31, 2023 27.1B5.7B 20.9% 4.50 3.00 67%
2022Dec 31, 2022 27.3B4.6B 16.8% 3.64 2.92 80%
2021Dec 31, 2021 27.3B6.2B 22.8% 4.93 2.84 58%
2020Dec 31, 2020 24.7B123.0M 0.5% 0.10 2.72 2,720%
2019Dec 31, 2019 22.4B5.4B 24.0% 4.22 2.52 60%
2018Dec 31, 2018 22.1B5.5B 24.7% 4.17 2.28 55%
2017Dec 31, 2017 26.1B4.6B 17.7% 3.51 2.08 59%
2016Dec 31, 2016 30.4B13.5B 44.4% 9.94 1.84 19%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q2/26Jun 30, 2026 7.8B−10.5B −134.5% −8.45 0.82 –
Q1/26Mar 31, 2026 7.0B2.0B 29.0% 1.61 0.82 51%
Q4/25*Dec 31, 2025 7.9B2.2B 27.5% – 0.79 –
Q3/25Sep 30, 2025 7.8B3.1B 39.3% 2.43 0.79 33%
Q2/25Jun 30, 2025 7.1B2.0B 27.7% 1.56 0.79 51%
Q1/25Mar 31, 2025 6.7B1.3B 19.7% 1.04 0.79 76%
Q4/24*Dec 31, 2024 7.6B1.8B 23.6% – 0.77 –
Q3/24Sep 30, 2024 7.5B1.3B 16.6% 1.00 0.77 77%
Q2/24Jun 30, 2024 7.0B1.6B 23.2% 1.29 0.77 60%
Q1/24Mar 31, 2024 6.7B−4.2B −62.4% −3.34 0.77 –
Q4/23*Dec 31, 2023 7.1B1.4B 20.1% – 0.75 –
Q3/23Sep 30, 2023 7.1B2.2B 30.9% 1.73 0.75 43%

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $15.9M5 people −$15.9M
6 months $00 people $26.6M5 people −$26.6M
12 months $00 people $87.9M7 people −$87.9M

Latest transactions

  • Oct 15, 2026 Mercier Johanna Officer Open-market sale · 10b5-1 plan 3,000 shares · $468.7K · SEC
  • Oct 15, 2026 Dickinson Andrew D Chief financial officer (CFO) Open-market sale · 10b5-1 plan 3,000 shares · $468.7K · SEC
  • Oct 1, 2026 O'Day Daniel Patrick Chief executive (CEO), Director Open-market sale · 10b5-1 plan 3,000 shares · $445.9K · SEC
  • Oct 1, 2026 O'Day Daniel Patrick Chief executive (CEO), Director Open-market sale · 10b5-1 plan 12,000 shares · $1.8M · SEC
  • Sep 15, 2026 Mercier Johanna Officer Open-market sale · 10b5-1 plan 600 shares · $87.2K · SEC
  • Sep 15, 2026 Mercier Johanna Officer Open-market sale · 10b5-1 plan 800 shares · $115.6K · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Trend score +75

Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+0
Highs and lows+10
Relative strength+15

Volatility and trend strength

ADX 14 (trend strength)22.6
Rel. strength 60 d+20.1%

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on GILD yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: GILD

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly (buy zones every 4 hours), stocks twice a day, precious metals every 4 hours on trading days, extended universe weekly – not in real time.

Log in Sign up free

↑ ↓ select · Enter open · Esc close